topic

Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models
Kristin Stirm, Peter Leary, Daria Wüst, Dominique Stark, Nicole Joller, Ufuk Karakus, Onur Boyman, Alexandar Tzankov, Anne Müller

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006263; DOI: 10.1136/jitc-2022-006263
Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
Jasmine I Caulfield, Lilach Aizenbud, Ana Luisa Perdigoto, Eric Meffre, Lucia Jilaveanu, Dominika A Michalek, Stephen S Rich, Yariv Aizenbud, Adebowale Adeniran, Kevan C Herold, Matthew R Austin, Harriet Kluger

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006570; DOI: 10.1136/jitc-2022-006570
Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells
Shi Yong Neo, Xu Jing, Le Tong, Dongmei Tong, Juan Gao, Ziqing Chen, Mireia Cruz De Los Santos, Nutsa Burduli, Sabrina De Souza Ferreira, Arnika Kathleen Wagner, Evren Alici, Charlotte Rolny, Yihai Cao, Andreas Lundqvist

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005308; DOI: 10.1136/jitc-2022-005308
Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al
Zinal S Chheda, Sabine Mueller, Bindu Hegde, Akane Yamamichi, Lisa H Butterfield, Hideho Okada

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006617; DOI: 10.1136/jitc-2022-006617
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
Lieke L van der Woude, Mark A J Gorris, Inge M N Wortel, Jeroen H A Creemers, Kiek Verrijp, Kim Monkhorst, Katrien Grünberg, Michel M van den Heuvel, Johannes Textor, Carl G Figdor, Berber Piet, Willemijn S M E Theelen, I Jolanda M de Vries

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005248; DOI: 10.1136/jitc-2022-005248
Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e004223corr1; DOI: 10.1136/jitc-2021-004223corr1
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
Adrienne G Waks, Tanya E Keenan, Tianyu Li, Nabihah Tayob, Gerburg M Wulf, Edward T Richardson, Victoria Attaya, Leilani Anderson, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Ian E Krop, Judith Agudo, Eliezer M Van Allen, Sara M Tolaney

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005119; DOI: 10.1136/jitc-2022-005119
First communication on the efficacy of combined ¹⁷⁷Lutetium-PSMA with immunotherapy outside prostate cancer
Antonia Digklia, Sarah Boughdad, Krisztian Homicsko, Clarisse Dromain, Mounir Trimech, Ana Dolcan, Solange Peters, John Prior, Niklaus Schaefer

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005383; DOI: 10.1136/jitc-2022-005383
Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization
Qi Zhang, Bingqiu Xiu, Liyi Zhang, Ming Chen, Weiru Chi, Lun Li, Rong Guo, Jingyan Xue, Benlong Yang, Xiaoyan Huang, Zhi-Ming Shao, Shenglin Huang, Yayun Chi, Jiong Wu

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e004666; DOI: 10.1136/jitc-2022-004666
Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
Jake G Maule, Lani K Clinton, Ryon P Graf, Jinpeng Xiao, Geoffrey R Oxnard, Jeffrey S Ross, Richard S P Huang

Journal for ImmunoTherapy of Cancer Oct 2022, 10 (10) e005573; DOI: 10.1136/jitc-2022-005573

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages